Literature DB >> 8685137

[Osteoporosis in ankylosing spondylitis].

E Toussirot1, D Wendling.   

Abstract

Bone formation is classically observed in ankylosing spondylitis, but osteoporosis can also occur. This condition has been recognized for years on radiographs. Compared with controls, osteoporosis in ankylosing spondylitis is responsible for increasing the incidence of vertebral compression fractures and also explains spinal fractures after trauma, mainly observed at the cervical level. Measurement of bone mass is useful in diagnosing osteoporosis commonly observed in the lumbar spine and the femoral neck but not in the appendicular skeleton. Osteoporosis is seen early in the disease whereas increased bone mass is observed later or due to syndesmophyte formation. Osteoporosis in ankylosing spondylitis is probably a multi-factorial condition. Contributing factors are spine immobility secondary to ankylosis, inflammatory cytokines which enhance bone resorption, prolonged use of nonsteroidal antiinflammatory drugs and a deficit in sex hormone secretion. Furthermore, there is no alteration in calcium or phosphorus metabolism in ankylosing spondylitis. Finally, a study of bone morphometrics in the iliac crest region is required to better explain osteoporosis in ankylosing spondylitis.

Entities:  

Mesh:

Year:  1996        PMID: 8685137

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  8 in total

1.  Bone and stone in ankylosing spondylitis: osteoporosis and urolithiasis.

Authors:  Nurgül Arinci Incel; Figen Gökoğlu; Bariş Nacir; Nazmi Incel
Journal:  Clin Rheumatol       Date:  2005-12-07       Impact factor: 2.980

2.  Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation.

Authors:  Chun-Hsiung Chen; Hung-An Chen; Hsien-Tzung Liao; Chin-Hsiu Liu; Chang-Youh Tsai; Chung-Tei Chou
Journal:  Clin Rheumatol       Date:  2010-08-06       Impact factor: 2.980

Review 3.  Therapeutic Potential of Triptolide in Treating Bone-Related Disorders.

Authors:  Wu Gang; Hu Hao; Huang Yong; Feng Ruibing; Li Chaowen; Huang Yizheng; Li Chao; Zhang Haitao
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 4.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

5.  A case of post-pregnancy osteoporosis combined with ankylosing spondylitis.

Authors:  Jeong Yoon Jang; Jae Gun Lee; In-Kyung Jeong; Kyu Jeong Ahn; Ho Yeon Chung; Hyung-In Yang; Sang-Hoon Lee
Journal:  Rheumatol Int       Date:  2008-12-12       Impact factor: 2.631

6.  Symptomatic improvement in function and disease activity in a patient with ankylosing spondylitis utilizing a course of chiropractic therapy: a prospective case study.

Authors:  Susan M Rutherford; Cameron F Nicolson; Edward R Crowther
Journal:  J Can Chiropr Assoc       Date:  2005-06

7.  IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.

Authors:  Fernanda Genre; Raquel López-Mejías; Javier Rueda-Gotor; José A Miranda-Filloy; Begoña Ubilla; Aurelia Villar-Bonet; Beatriz Carnero-López; Inés Gómez-Acebo; Ricardo Blanco; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

8.  Nephrolithiasis in ankylosing spondylitis and its relationship with disease assessment scales.

Authors:  Aylin Rezvani; Ilknur Aktas; Nurettin Tastekin; Reyhan Celiker; Selda Sarikaya; Erbil Dursun; Senay Ozdolap; Nigar Dursun; Coskun Zateri; Lale Altan; Murat Birtane; Kenan Akgun; Necdet Sut
Journal:  North Clin Istanb       Date:  2018-08-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.